Quarterly report pursuant to Section 13 or 15(d)

License Agreements - Additional Information (Detail)

v3.24.3
License Agreements - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
May 14, 2015
Sep. 30, 2024
Sep. 30, 2024
Dec. 31, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Cash   $ 100 $ 100  
Fair value of the contingent consideration   699 699 $ 528
Loss on contingent consideration   62 171  
Sopharma [Member] | Share Purchase Agreement [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Percentage of outstanding shares acquired 75.00%      
Cash $ 2,000      
Deferred payment $ 2,000      
Fair value of the contingent consideration   700 700  
Loss on contingent consideration   $ 100 $ 200